Biotech firm GangaGen, based in Palo Alto, Calif., brought in $5.4 million in fifth-round funding from ATEL Ventures, Otsuka Pharmaceuticals and ICF Ltd. to develop treatments for bacterial infections. The company specializes in antibiotic-resistant strains of bacteria, like Staphylococcus, in the medical, veterinary and agricultural areas. It currently has a preventative prophylactic and a topical treatment for wounds and burns in the works.